Hexagon Nutrition Ltd
- Market cap
- ₹ 753 Cr.
- P/E
- 19.6x
- P/B
- 3.26x
- 52-week range
- 48.1 – 78.25
- ROE
- 16%
- ROCE
- 15%
- Debt / equity
- 0.14
- Sector
- Food Products
- Industry
- Packaged Foods
- Listed on
- NSE, BSE
About
Hexagon Nutrition Limited is an India-based research-oriented pure play nutrition company. The Company is engaged in the manufacturing and trading of nutraceuticals clinical or dietary supplements, micronutrient premixes and animal feed. Its product portfolio is classified into three segments: Branded nutrition products/ clinical nutrition products (B2C segment), Premix formulations (B2B2C segment), and Ready to use foods (RUFs) and Micro Nutrient Powder (MNPs) (ESG segment). The B2C segment offers branded wellness and clinical nutrition products encompassing daily nutritional requirements across demographics from pediatric to geriatric nutrition. Its B2B2C segment offers customized micronutrient formulation in the form of vitamin and mineral premixes that are supplied to Indian and multi-national fast-moving consumer goods players for fortification of consumer products. The ESG segment offers therapeutic foods in two forms: nutrient-dense RUFs in paste form and Micronutrient Powders.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Packaged Foods: 56 companies →Hexagon Nutrition Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.6 against a typical 42.7: cheaper than most peers (1st = cheapest).19th of 56
- Sales growth+21.5% against a typical +15.3% from a year earlier.17th of 45
- Profit growth+48% against a typical +7.5% from a year earlier.7th of 40
- Share price, 3 months−7% against a typical −10.1%.21st of 51
- Size₹ 753.2 Cr. market value against a typical ₹ 99 Cr. (1st = largest).11th of 53
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A- | Stable | 7 Aug 2026 |
| CARE | CARE A- | Stable | 31 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Aug 2026 | Rating action | [ICRA]A- | — | ICRA | ₹ 65 Cr. | |
| 31 Jul 2026 | New rating | CARE A- | — | CARE | ₹ 66 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Sep 2026 | Other business matters | To consider other business matters |
| 12 Aug 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026, dividend and other business matters |
| 30 Jun 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 83 | 63 | 82 | 98 | 101 |
| Expenses | 75 | 56 | 70 | 84 | 89 |
| Operating Profit | 9 | 8 | 12 | 14 | 12 |
| OPM % | 10.3% | 12% | 15% | 14.2% | 12.1% |
| Other Income | 2 | 2 | 3 | 6 | 3 |
| Interest | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 2 | 1 |
| Profit before tax | 9 | 8 | 13 | 18 | 13 |
| Tax % | 25.6% | 25.3% | 26.4% | 25.1% | 25.7% |
| Net Profit | 7 | 6 | 10 | 14 | 10 |
| EPS in Rs | 0.6 | 0.54 | 0.89 | 1.23 | 0.8 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 30%
- 3 Years
- 41%
- TTM
- —
- 10 Years
- —
- 5 Years
- 52%
- 3 Years
- 273%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Hexagon Nutrition Ltd | ₹ 73.80 | ₹ 753 Cr. | 19.6x | 3.3x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Arun Purushottam Kelkar
- Executive Chairman of the Board
- Soman Nemai Jana
- Chief Financial Officer
- Vedanti Swapnil Vartak
- Company Secretary, Compliance Officer
- Nikhil Arun Kelkar
- Joint Managing Director, Executive Director
- Vikram Arun Kelkar
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.